Histology
Mucinous Neoplasm
CI-CAN-00001237Explore in graph →
Non-malignant37 active trials4 evidence items
- NCIt
- C7070
Loading cancer entity…
Histology
CI-CAN-00001237Explore in graph →
Clinical trials
178 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | active not recruiting | Phase 3 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI) |
| 1 |
| Jun 2, 2026 |
| clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT02879513 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | unknown | Phase 3 | 290 | RenJi HospitalOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | completed | Phase 3 | 225 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2018 | clinicaltrials |
| NCT00719303 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 3 | 1,070 | Gynecologic Oncology GroupNETWORK | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00689715 | Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas(EUS-EP) | unknown | Phase 2 / Phase 3 | 50 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT00005036 | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | completed | Phase 3 | 560 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials